FR4727M - Hydroxyproline and its drug combinations in the treatment of rheumatic diseases. - Google Patents

Hydroxyproline and its drug combinations in the treatment of rheumatic diseases. Download PDF

Info

Publication number
FR4727M
FR4727M FR37265A FR37265A FR4727M FR 4727 M FR4727 M FR 4727M FR 37265 A FR37265 A FR 37265A FR 37265 A FR37265 A FR 37265A FR 4727 M FR4727 M FR 4727M
Authority
FR
France
Prior art keywords
hydroxyproline
glucosamine
treatment
rheumatic diseases
drug combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR37265A
Other languages
French (fr)
Inventor
J C Denis
J Rambaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tecpan SA
Original Assignee
Tecpan SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecpan SA filed Critical Tecpan SA
Priority to FR37265A priority Critical patent/FR4727M/en
Priority to BE688490A priority patent/BE688490A/en
Priority to NL6615581A priority patent/NL6615581A/en
Application granted granted Critical
Publication of FR4727M publication Critical patent/FR4727M/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/618Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

REPUBLIQUE FRANÇAISEFRENCH REPUBLIC

MINISTERE DE L'INDUSTRIEMINISTRY OF INDUSTRY

SERVICE de la PROPRIÉTÉ INDUSTRIELLEINDUSTRIAL PROPERTY SERVICE

BREVET SPÉCIAL DE MÉDICAMENTSPECIAL MEDICINAL PATENT

P.V. n° 37.265 Classification internationaleP.V. n ° 37.265 International Classification

N° 4.727 M A 61kN ° 4.727 M A 61k

La 1 . hydroxyproline et ses associations médicamenteuses dans 1 etraWëHfôïîfif de s maladies rhumatismales. (Invention : J.-C. Denis et J. Rambaud.) HGINDCV;The 1. hydroxyproline and its drug combinations in the etraWëHfôifif of rheumatic diseases. (Invention: J.-C. Denis and J. Rambaud.) HGINDCV;

14» m h h oh h14 »m h h oh h

! I I I chaoh-c—c—c—c-cho I I I ! oh oh h nh2! I I I chaoh-c — c — c — c-cho I I I! oh oh h nh2

cehiaosn = 179,17cehiaosn = 179.17

La l.hydroxyproline a pour formule :The formula of l.hydroxyproline:

hoho

\\

hc h2chc h2c

-ch2-ch2

II

chch

\n\not

COO-COO-

c5h903n = 131,13c5h903n = 131.13

Propriétés pharmacodynamiques. — Le chlorhydrate de glucosamine et la l.hydroxyproline ont été administrés chez l'animal, respectivement à la dose de 150 et 15 mg/kg, dans les différents tests servant habituellement à mesurer l'action analgésique et l'action anti-inflammatoire des médicaments. Parmi ceux-ci citons notamment le syndrome de torsion provoqué chez la souris par la phényl-benzoquinone, l'inhibition de la douleur provoquée par l'inflammation expérimentale de la patte du rat, l'inflammation provoquée par les pellets de coton ou l'injection d'essence de térébenthine.Pharmacodynamic properties. - Glucosamine hydrochloride and l.hydroxyproline were administered to animals, respectively at a dose of 150 and 15 mg / kg, in the various tests usually used to measure the analgesic action and the anti-inflammatory action of drugs. These include, but are not limited to, torsion syndrome caused in mice by phenyl-benzoquinone, inhibition of pain caused by experimental inflammation of the rat paw, inflammation caused by cotton pellets or turpentine gasoline injection.

Le chlorhydrate de glucosamine et la l.hydroxyproline ont également été administrés à l'animal en association avec les antirhumatismaux connus et notamment :Glucosamine hydrochloride and l.hydroxyproline have also been administered to animals in combination with known anti-rheumatic drugs including:

Acide acétylsalicylique et salicylates;Acetylsalicylic acid and salicylates;

Acétyl p.aminophénol ;Acetyl p.aminophenol;

Phényl - 1 - diméthyl - 2 - 3 - isopyrazolone (antipyrine) ;Phenyl - 1 - dimethyl - 2 - 3 - isopyrazolone (antipyrine);

7 210551 7 •+. prix du fascicule7 210551 7 • +. price of the booklet

Société dite : TECPAN S. A. résidant au Mexique.Company known as: TECPAN S. A. residing in Mexico.

Demandé le 4 novembre 1965, à 15h 3m, à l'aris.Requested on November 4, 1965, at 3 p.m. 3m, at the aris.

Délivré par arrêté du 2 janvier 1967. [Issued by decree of January 2, 1967. [

{Bulletin officiel de la Propriété industrielle [5.5.M.], n° 6 du 6 février 1967.){Official Bulletin of Industrial Property [5.5.M.], No. 6 of February 6, 1967.)

La présente invention consiste en l'utilisation de la l.hydroxyproline en association :The present invention consists of the use of l.hydroxyproline in combination:

- Avec la glucosamine (ou un de ses sels comme chlorhydrate) ;- With glucosamine (or one of its salts as hydrochloride);

Ou avec un médicament antirhumastimal ;Or with an antirhumastimal drug;

Ou avec la glucosamine et un médicament anti-rhumatismal.Or with glucosamine and an anti-rheumatic drug.

La glucosamine a pour formule :Glucosamine has the following formula:

3,5 - dioxo -3.5 - dioxo -

Phényl - 1 - diméthyl^' 2*^"3 '- diméthylamino - 4 pyrazolone (amidopyrine) ;Phenyl - 1 - dimethyl ^ '2 * ^ "3' - 4-dimethylamino-pyrazolone (amidopyrine);

Dioxy - 3,5 diphényl - 1,2 n - butyl - 4 - pyrazo-lidine (phénylbutazone) ;Dioxy - 3,5 diphenyl - 1,2 n - butyl - 4 - pyrazo-lidine (phenylbutazone);

1 - phényl - 2(p.hydroxyphényl)1 - phenyl - 2 (p.hydroxyphenyl)

4 - n - butyl - pyrazolidine ;4 - n - butyl - pyrazolidine;

Griséofulvine ;Griseofulvin;

Hydroxychloroquine ;Hydroxychloroquine ;

Extrait de cartilage articulaire et de moelle osseuse.Extract of articular cartilage and bone marrow.

Les tests pharmacodynamiques ont mis en évidence :Pharmacodynamic tests revealed:

1° L'intérêt d'employer simultanément la glucosamine avec la l.hydroxyproline pour obtenir un , effet anti-inflammatoi're ;1 ° The advantage of simultaneously using glucosamine with l.hydroxyproline to obtain an anti-inflammatory effect;

2° L'intérêt d'adjoindre à la l.hydroxyproline ou à l'association glucosamine - l.hydroxyproline, un médicament antirhumatismal, tel que ceux cités plus haut, si l'on désire obtenir un effet plus rapide et plus important.2 ° The advantage of adding to l.hydroxyproline or to the glucosamine - l.hydroxyproline combination, an antirheumatic drug, such as those mentioned above, if one wishes to obtain a faster and more important effect.

En effet, la l.hydroxyproline et plus encore l'association glucosamine-hydroxyproline non seulement potentialisent les effets des médicaments antirhumatismaux mais aussi prolongent leur action dans le temps et permettent de les employer, pour une même efficacité, à des doses plus faibles et donc moins toxiques.Indeed, l.hydroxyproline and even more the glucosamine-hydroxyproline combination not only potentiate the effects of anti-rheumatic drugs but also prolong their action over time and allow them to be used, for the same effectiveness, at lower doses and therefore less toxic.

Applications thérapeutiques. — La l.hydroxyproline et l'association glucosamine - l.hydroxyproline peuvent être utilisées avec succès dans les différentes affections rhumatismales, soit seules soit simultanément avec les autres médications connues, selon les exemples ci-dessous :Therapeutic applications. - l.hydroxyproline and the glucosamine - l.hydroxyproline combination can be used successfully in various rheumatic conditions, either alone or simultaneously with other known medications, according to the examples below:

Chl. de glucosamine, g 0,200Chl. glucosamine, g 0.200

1. hydroxyproline, g, 0,0201.hydroxyproline, g, 0.020

Excipient q.s. pour un comprimé.Excipient q.s. for one tablet.

4 à 6 comprimés par jour comme fond des affections rhumatismales ;4 to 6 tablets per day as a background for rheumatic affections;

traitement de b. Acétyl p. aminophénol, g 0,400treatment of b. Acetyl p. aminophenol, g 0.400

l.hydroxyproline, g 0,010l. hydroxyproline, g 0.010

2 francs2 francs

[4.727 M][4.727 M]

4 à 6 comprimés par jour, dans les algies rhumatismales ;4 to 6 tablets per day, in rheumatic pain;

c. Acide acétylsalicylique, g 0,250vs. Acetylsalicylic acid, g 0.250

Chl. de glucosamine, g 0,150Chl. glucosamine, g 0.150

1. hydroxyproline, g 0,0151.hydroxyproline, g 0.015

Excipient q.s. pour un comprimé.Excipient q.s. for one tablet.

6 comprimés par jour, dans toutes les algies rhumatismales ;6 tablets per day, for all rheumatic pain;

■d. Dioxy- ,3,5 -diphényl-1,2 -re-butyl-4- 0,100 pyrazolidine, g.■ d. Dioxy-, 3,5 -diphenyl-1,2 -re-butyl-4- 0.100 pyrazolidine, g.

Chl. de glucosamine, g 0,100Chl. glucosamine, g 0.100

1. hydroxyproline, g 0,0101.hydroxyproline, g 0.010

Excipient q.s. pour un comprimé.Excipient q.s. for one tablet.

1 à 2 comprimés par jour dans les cas de rhumatisme articulaire aigu, polyarthrite rhumatoïde, arthrose, périarthrite, phlébite.1 to 2 tablets per day in cases of rheumatic fever, rheumatoid arthritis, arthritis, periarthritis, phlebitis.

Formes pharmaceutiques. — La glucosamine, ou l'un de ses sels comme le chlorhydrate de glucosamine, et la l.hydroxyproline pourront être utilisés :Pharmaceutical forms. - Glucosamine, or one of its salts such as glucosamine hydrochloride, and l.hydroxyproline can be used:

Soit en solution sous une présentation pharma-ceutiquement acceptable comme les ampoules injectables ou buvables, les sirops, les solutions;Either in solution in a pharma-ceutically acceptable presentation such as injectable or drinkable ampoules, syrups, solutions;

Soit à l'état de poudre sous une présentation pharmaceutiquement acceptable qui pourra être celle de comprimés, gélules, sachets, granulés, suppositoires, seuls ou en association avec d'autres médicaments ou composés pharmaceutiquement acceptables.Either in the powder form in a pharmaceutically acceptable presentation which may be that of tablets, capsules, sachets, granules, suppositories, alone or in combination with other drugs or pharmaceutically acceptable compounds.

RÉSUMÉABSTRACT

1° La présente invention a pour objet l'utilisation de la l.hydroxyproline en association avec la glucosamine (ou un de ses sels comme le chlorhydrate), ou avec un médicament antirhumatismal, ou avec la glucosamine et un médicament antirhumatismal, dans le traitement des maladies rhumatismales.1 ° The present invention relates to the use of l.hydroxyproline in combination with glucosamine (or one of its salts such as hydrochloride), or with an antirheumatic drug, or with glucosamine and an antirheumatic drug, in the treatment rheumatic diseases.

2° L'adjonction de la l.hydroxyproline et plus encore de l'association l.hydroxyproline-chl. de glucosamine à un médicament antirhumatismal détermine une activité thérapeutique plus importante, plus durable et moins toxique que celle que l'on aurait obtenue 'avec le produit antirhumatismal administré isolément.2 ° The addition of l.hydroxyproline and even more of the l.hydroxyproline-chl association. of glucosamine to an antirheumatic drug results in greater, longer lasting and less toxic therapeutic activity than that which would have been obtained with the antirheumatic drug administered alone.

Société dite : TECPAN S. A.Company known as: TECPAN S. A.

Par procuration :Vicarious :

BlétryBlétry

AVIS DOCUMENTAIRE SUR LA NOUVEAUTÉDOCUMENTARY NOTICE ON THE NEW FEATURE

Documents susceptibles de porter atteinte à la nouveauté du médicament : néant.Documents likely to affect the novelty of the medicinal product: none.

Documents illustrant l'état de la technique en la matière : néant.Documents illustrating the state of the art in this area: none.

Pour la vente des fascicules, s'adresser à I'Imprimerie Nationale, 27, rue de la Convention, Paris (15e).For the sale of booklets, contact the Imprimerie Nationale, 27, rue de la Convention, Paris (15th).

FR37265A 1965-11-04 1965-11-04 Hydroxyproline and its drug combinations in the treatment of rheumatic diseases. Expired FR4727M (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR37265A FR4727M (en) 1965-11-04 1965-11-04 Hydroxyproline and its drug combinations in the treatment of rheumatic diseases.
BE688490A BE688490A (en) 1965-11-04 1966-10-19 1.hydroxyproline and its drug combinations in the treatment of connective tissue diseases.
NL6615581A NL6615581A (en) 1965-11-04 1966-11-04 A method of preparing a therapeutic composition for treating connective tissue diseases.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR37265A FR4727M (en) 1965-11-04 1965-11-04 Hydroxyproline and its drug combinations in the treatment of rheumatic diseases.

Publications (1)

Publication Number Publication Date
FR4727M true FR4727M (en) 1967-02-06

Family

ID=8591826

Family Applications (1)

Application Number Title Priority Date Filing Date
FR37265A Expired FR4727M (en) 1965-11-04 1965-11-04 Hydroxyproline and its drug combinations in the treatment of rheumatic diseases.

Country Status (3)

Country Link
BE (1) BE688490A (en)
FR (1) FR4727M (en)
NL (1) NL6615581A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0740938A2 (en) * 1995-05-05 1996-11-06 IPR-Institute for Pharmaceutical Research Riehen AG Proline and 4-hydroxyproline as therapeutic agents
EP1356811A1 (en) * 2001-01-05 2003-10-29 Kyowa Hakko Kogyo Co., Ltd. Preventives or remedies for arthritis

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0740938A2 (en) * 1995-05-05 1996-11-06 IPR-Institute for Pharmaceutical Research Riehen AG Proline and 4-hydroxyproline as therapeutic agents
EP0740938A3 (en) * 1995-05-05 1997-03-12 Ipr Inst Pharm Res Riehen Ag Proline and 4-hydroxyproline as therapeutic agents
EP1356811A1 (en) * 2001-01-05 2003-10-29 Kyowa Hakko Kogyo Co., Ltd. Preventives or remedies for arthritis
EP1356811A4 (en) * 2001-01-05 2005-08-17 Kyowa Hakko Kogyo Kk Preventives or remedies for arthritis
US7138386B2 (en) 2001-01-05 2006-11-21 Kyowa Hakko Kogyo Co., Ltd. Preventives or remedies for arthritis

Also Published As

Publication number Publication date
BE688490A (en) 1967-03-31
NL6615581A (en) 1967-05-05

Similar Documents

Publication Publication Date Title
Carlsson et al. Inhibition of ethanol-induced excitation in mice and rats by α-methyl-p-tyrosine
CA1241604A (en) Pharmaceutical products providing enhanced analgesia
AR028299A1 (en) A PHARMACEUTICAL COMPOSITION THAT INCLUDES NATEGLINIDA, A PROCESS FOR ITS PREPARATION AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETY.
DE69931640T2 (en) USE OF ACETYLCHOLINESTERASIS INHIBITORS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF FUNCTIONAL AND / OR ORGANIC PAIN SYNDROME
KR20020025221A (en) Composition comprising a tramadol material and an anticonvulsant drug
MA32056B1 (en) Stop oral medications that contain paracetamol and ibuprofen
PT1992333E (en) Flurbiprofen and muscle relaxant combinations
JPH0465050B2 (en)
JPS59501413A (en) Improved analgesic and anti-inflammatory compositions containing ibuprofen
FR4727M (en) Hydroxyproline and its drug combinations in the treatment of rheumatic diseases.
GB2287404A (en) Antiinflammatory and analgesic compositions
CN100358515C (en) Treatment of neurodegenerative and cardiovascular disorders
JPH01311022A (en) 3-substituted-2-oxyindole-1-carboxamide for suppressing t-cell function
Weinstock Acetylcholine and cholinesterase
CN103384522A (en) Caffeic acid derivatives and their use in improving neuronal cell viability
JPS59205321A (en) Anthelmintic synergistical novel composition
US1716686A (en) Pharmaceutical
JP2752250B2 (en) Basic therapeutic agent with analgesic and anti-inflammatory action
FR1759M (en)
Tsay et al. Pharmaceutical and Biological Effects of Suramin and Potential of Its Derivatives and Analogues
Waldeck Modification of the caffeine-induced locomotor stimulation by a cholinergic mechanism
Alexandr et al. Osteoarthrosis: possibilities of complex use of the medication Zeel T within the framework of bioregulatory approach
FR100F (en) New drug endowed in particular with antimitotic activity.
KR950700063A (en) Brofaromine as an agent for treating post-traumatic stress
Syrova et al. Experimental study of the antipyretic effect of oxicams and their compositions with caffeine